Bessemer Group Inc. Raises Holdings in Smith & Nephew SNATS, Inc. $SNN

Bessemer Group Inc. grew its position in Smith & Nephew SNATS, Inc. (NYSE:SNN) by 111.9% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,709 shares of the medical equipment provider’s stock after buying an additional 1,959 shares during the quarter. Bessemer Group Inc.’s holdings in Smith & Nephew SNATS were worth $114,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Hexagon Capital Partners LLC boosted its position in Smith & Nephew SNATS by 63.3% during the first quarter. Hexagon Capital Partners LLC now owns 1,047 shares of the medical equipment provider’s stock valued at $30,000 after purchasing an additional 406 shares in the last quarter. Richards Merrill & Peterson Inc. boosted its position in Smith & Nephew SNATS by 500.0% during the first quarter. Richards Merrill & Peterson Inc. now owns 1,200 shares of the medical equipment provider’s stock valued at $34,000 after purchasing an additional 1,000 shares in the last quarter. Banque Transatlantique SA bought a new stake in Smith & Nephew SNATS during the first quarter valued at about $52,000. Geneos Wealth Management Inc. boosted its position in Smith & Nephew SNATS by 15.0% during the first quarter. Geneos Wealth Management Inc. now owns 4,149 shares of the medical equipment provider’s stock valued at $118,000 after purchasing an additional 541 shares in the last quarter. Finally, Brooklyn Investment Group boosted its position in Smith & Nephew SNATS by 3,086.3% during the first quarter. Brooklyn Investment Group now owns 4,429 shares of the medical equipment provider’s stock valued at $126,000 after purchasing an additional 4,290 shares in the last quarter. 25.64% of the stock is currently owned by hedge funds and other institutional investors.

Smith & Nephew SNATS Stock Up 0.8%

Shares of SNN opened at $37.05 on Wednesday. The company has a current ratio of 3.00, a quick ratio of 1.40 and a debt-to-equity ratio of 0.60. Smith & Nephew SNATS, Inc. has a one year low of $23.69 and a one year high of $38.79. The stock has a 50 day moving average price of $36.65 and a 200 day moving average price of $32.71.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. Royal Bank Of Canada restated an “outperform” rating on shares of Smith & Nephew SNATS in a research note on Monday, October 20th. Weiss Ratings restated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research note on Wednesday, October 8th. Sanford C. Bernstein set a $37.50 price objective on Smith & Nephew SNATS and gave the stock a “market perform” rating in a research note on Tuesday, October 14th. Canaccord Genuity Group raised their price objective on Smith & Nephew SNATS from $28.00 to $36.00 and gave the stock a “hold” rating in a research note on Monday, August 18th. Finally, Wall Street Zen cut Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a research note on Friday, October 3rd. One equities research analyst has rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Smith & Nephew SNATS currently has an average rating of “Hold” and a consensus price target of $36.75.

Smith & Nephew SNATS Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.